WHAT WE DO
EuropaBio - The European Association for Bioindustries, is Europe's largest and most influential biotech industry group. Initiated in 1996 to represent the interests of the biotechnology industry at European level, and constantly engaged in a dialogue with the European Parliament, the European Commission and the Council of Ministers EuropaBio aims to influence legislation on biotechnology, representing Healthcare and Industrial biotechnology sectors.
- promoting an innovative, coherent, and dynamic biotechnology-based industry in Europe;
- advocating free and open markets and the removal of barriers to competitiveness with other areas of the world;
- committing to an open, transparent, and informed dialogue with all stakeholders about the ethical, social, and economic aspects of biotechnology and its benefits;
- championing the socially responsible use of biotechnology to ensure that its potential is fully used to the benefit of humans and their environment.
As its name suggests, EuropaBio's primary focuses on the European Union, but due to the global character of the biotech business, it also represents its members in transatlantic and worldwide forums.
Who We Are
EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs. EuropaBio has a Board of Management made up of representatives of member companies. The board is supported by the EuropaBio team who carry out day to day activities and is managed by a Director General.
Two main segments of Biotechnology are represented through sectoral councils: Healthcare (Red Biotech) and Industrial (White Biotech). Experts from member companies actively participate in working groups and task forces which cover a wide range of issues and concerns particular to their industry. Each council, working group or task force is chaired by a member and is coordinated by a EuropaBio staff member.
EuropaBio is a founding member of the International Council of Biotech Associations (ICBA).
Governance & Councils
MEMBERS OF THE BOARD
CHAIR OF THE ASSOCIATION
Ms. Patricia MALARKEY,
Chief Science Officer, representing Royal DSM
Dr. Ricardo GENT,
Managing Director, representing Deutsche Industrievereinigung Biotechnologie (DIB)
CHAIR OF THE HEALTHCARE BIOTECHNOLOGY COUNCIL
Mr. Neil MULCOCK,
Vice President Government Affairs & Policy, representing Gilead
CHAIR OF THE INDUSTRIAL BIOTECHNOLOGY COUNCIL
Prof. Dr. Stefan BUCHHOLZ,
Head of Research & Development for the Division Nutrition & Care, representing Evonik Operations GmbH
CHAIR OF THE NATIONAL ASSOCIATIONS COUNCIL
Mrs. Tineke VAN HOOLAND,
Deputy Secretary General, representing Bio.be
CHAIR OF THE SME PLATFORM
Dr. Maria Luisa NOLLI,
Member of the board of ASSOBIOTEC, representing ASSOBIOTEC
Mr. Ion AROCENA VELEZ,
General Manager, representing the Spanish Bioindustry Association (ASEBIO)
Mr. Steve BATES,
Chief Executive Officer, representing the BioIndustry Association (BIA)
Dr. Peter HEINRICH,
Chairman of BioDeutschland, representing BioDeutschland
Mr. Peter Steen MORTENSEN,
Director Global Public Affairs, representing Novozymes A/S
Prof. Dr. Arjen VAN TUNEN,
CEO, representing Keygene
Ms. Luana BANU,
Head of Public Policy, Communications and Patient Advocacy (Europe and Canada Business Unit), representing Takeda
Mr. Thomas BOLS,
Head of Government Affairs and Patient Advocacy, EMEA & APAC, representing PTC Therapeutics
Mr. Marcel LECHANTEUR,
President and General Manager Lilly France, Benelux, North West Africa and European Affairs, representing Lilly
Dr. Doreen SCHACHTSCHABEL,
Vice President R&D White Biotechnology, representing BASF
Mrs. Annemiek VERKAMMAN,
Managing Director, representing HollandBIO
Mr. David EARNSHAW,
Associate Vice President for Public Policy Europe & Canada, representing MSD Europe Inc.
Mr. Matt MORAN,
Director, representing BioPharmaChem Ireland
Mr. Andrew TOPEN,